Search

The article focuses on a study that found no significant increased risk of infection in older adults with inflammatory bowel disease (IBD) taking immunosuppressants. Topics include the evaluation of infection risk associated with advanced therapies like immunomodulators & biologics; methodology of using Medicare data to compare patients on advanced therapies versus nonimmunosuppressive drugs; and there was a slight increase in infection risk, it was not statistically significant.

The article reports on a phase 2 trial demonstrating that tulisokibart, an investigational monoclonal antibody targeting tumor necrosis-like cytokine 1A (TL1A). Topics include the trial's significant findings showing that 26% of patients on tulisokibart achieved clinical remission at week 12 compared to just 1% on placebo, the development of a genetic diagnostic test to identify likely responders to the treatment, and the conclusion that tulisokibart is safer and more effective than placebo.

The article reports on a study that found treatment with Entyvio (vedolizumab) followed by Humira (adalimumab) results in the lowest risk of adverse events for patients with ulcerative colitis (UC). Topics include the comparative analysis of biologic treatment sequences for inflammatory bowel disease (IBD); the evaluation of various first- and second-line biologics; and the study's implications for clinical decision-making in treating patients with moderate to severe IBD.

The article discusses the progress of bruton tyrosine kinase (BTK) inhibitors in the treatment of multiple sclerosis (MS), with several drugmakers advancing in clinical trials. Topics include the role of BTK in MS pathology, the progress of BTK inhibitors like tolebrutinib, fenebrutinib, and remibrutinib in late-stage trials, and the challenges posed by liver toxicity and treatment efficacy in various MS subtypes.

The article focuses on the mismatch between the visual representation of inflammatory bowel disease (IBD) in media and the actual demographics of the patient population. Topics include the influence of these depictions on public and professional perceptions, the stigma associated with IBD, and the methods used in a recent study to analyze the portrayal of IBD in online images and television commercials.

The article discusses the rising out-of-pocket costs for disease-modifying therapies (DMTs) used to treat multiple sclerosis (MS). A study led by Amanda V. Gusovsky and colleagues compared costs for MS drugs with those for other neurologic conditions, revealing a 217% increase in out-of-pocket costs for MS DMTs from 2012 to 2021. Additionally, the article highlights the issue of upcoding in healthcare, with a RAND study showing a 41% increase in discharges with the highest severity level, potentially leading to increased payments to hospitals. [Extracted from the article]

The article discusses upcoming drug approvals in the second half of 2024. One potential approval is KarXT, an antipsychotic that does not have the side effects of other antipsychotics because it does not affect dopamine receptors. Other potential approvals include OX124 for opioid overdose, Alpha-1062 for Alzheimer's disease, Seladelpar for primary biliary cholangitis, and Acoramidis for a rare form of cardiomyopathy. The article provides information on each drug's development, clinical trials, and the FDA's target action dates for approval. [Extracted from the article]

The article explores the rising prominence of GLP-1 receptor agonists, particularly in weight management and diabetes treatment, dominating discussions in both medical circles and popular culture. Topics include the development of oral GLP-1 agonists, dual agonists like tirzepatide, and the promising prospects of triple agonists such as retatrutide, signifying a burgeoning market for innovative therapies in obesity and diabetes management.

The article focuses on Janus kinases (JAKs), a group of inflammatory proteins linked to various inflammatory and autoimmune disorders, particularly in dermatology, including alopecia areata. JAK inhibitors, which suppress inflammatory cytokines by targeting the JAK-STAT pathway, have gained prominence in dermatological treatment, with deuruxolitinib emerging as a potential therapy for moderate to severe alopecia areata, receiving breakthrough therapy and fast track designation from the FDA.

The article focuses on the resurgence of optimism surrounding Antibody-Drug Conjugates (ADCs) in oncology treatment, marked by over a dozen FDA approvals and an estimated market value of 9.7 billion U.S. dollar, with projections indicating a potential doubling by 2028. ADCs, likened to guided missiles, consist of three elements: cancer-targeting antibodies, linkers to connect the antibodies to cytotoxic drugs.

The article focuses on the resurgence of research into psychedelics for psychiatric conditions, tracing back to the lifting of restrictions in 1992, and highlights the recent FDA guidance on conducting clinical trials for psychedelic agents, along with ongoing research on substances like ketamine, MDMA, and psilocybin for conditions such as alcohol use disorder, PTSD, and treatment-resistant depression.

The article discusses the advancement of antibody-drug conjugates (ADCs) for treating triple-negative breast cancer (TNBC), an aggressive form with low survival rates. Topics discussed include the development of Trophoblast Cell Surface Antigen (TROP2)-targeted ADCs, such as datopotamab deruxtecan and sacituzumab tirumotecan, their clinical trials, and their potential to improve outcomes compared to traditional chemotherapy.

The article focuses on the expansion of mRNA vaccine technology beyond COVID-19, with companies like Pfizer and Moderna investigating its potential for seasonal influenza, cytomegalovirus (CMV), Zika virus, genital herpes, and HIV, highlighting ongoing clinical trials and the development progress of various mRNA vaccine candidates targeting these infectious diseases.

The article presents the Pfizer and Moderna vaccines have full FDA approval, but many candidates are in phase 2 or 3 trials.

The article discusses the development of potential treatments for non-small cell lung cancer (NSCLC), the most common lung cancer type. It is reported that researchers has been focusing on the c-MET protein, which is overexpressed in NSCLC and associated with poor prognosis. It is further reported that two drugs, savolitinib and Teliso-V, are in phase 3 clinical trials targeting c-MET in NSCLC.

The article offers information on the development of selective estrogen receptor degraders (SERDs) as a new class of drugs for the treatment of estrogen receptor (ER) positive breast cancers. These drugs, such as AstraZeneca's Faslodex and Menarini Group's Orserdu, aim to combat drug resistance by binding to ERs and causing their degradation.

The article informs the FDA granted approvals to 22 new drugs, including notable newcomers such as Inpefa for heart failure, Miebo for dry eye disease, and Veozah for hot flashes associated with menopause. Additionally, a maternal vaccine for RSV infections in children has shown promising results, and Eli Lilly's Mounjaro, has demonstrated significant weight loss effects in clinical trials and is expected to compete against other weight loss drugs in the market.

The article focuses on lipoprotein(a) as a cardiovascular disease risk factor, which remains unchanged by diet and exercise. Topics discussed include the challenges associated with lowering lipoprotein(a), the development of innovative treatments targeting the transcription process to reduce its production, and ongoing phase 3 trials evaluating the efficacy and safety of pelacarsen and olpasiran in adults with established cardiovascular disease and elevated lipoprotein(a) levels.

The article offers information about Duchenne muscular dystrophy (DMD), a progressive genetic disorder primarily affecting boys. It discusses the symptoms, available treatments, and advancements in disease-modifying treatments such as exon-skipping therapies and potential future treatments like gene replacement therapy for DMD.

The article provides updates on research related to Respiratory syncytial virus (RSV) is a highly contagious virus that can affect the lower respiratory tract, causing pneumonia and other respiratory tract infections and development of its vaccine. Pfizer has developed a bivalent RSV prefusion vaccine candidate called RSVpreF, which delivers synthetic forms of stabilized prefusion F protein, and has completed the phase 3 MATISSE trial.

The article focuses on three hemostatic rebalancing agents for the treatment of hemophilia that are in the late stages of development. The investigational RNA interference agent called Fitusiran increases the production of thrombin, which helps blood to clot by reducing the synthesis of antithrombin. Marstacimab is a monoclonal antibody that targets tissue factor pathway inhibitor (TFPI). Concizumab is also a subcutaneously administered TFPI-targeting recombinant antibody.

The article focuses on the mechanisms behind the reduced immune response and early waning of protection in patients with inflammatory bowel disease (IBD) treated with TNF-alpha blockers, particularly in relation to vaccination.

The article focuses on recent developments in Alzheimer's disease treatment. It highlights the approval of Leqembi (lecanemab) as the first Food and Drug Administration-approved amyloid beta-directed antibody and the promising results of the donanemab study, while also discussing the ongoing research into less invasive blood tests for Alzheimer's diagnosis.

The article offers information on the three companies which are in a race to be the first one to develop an IL-23 inhibitor monoclonal antibody for moderate to severe ulcerative colitis, a type of inflammatory bowel disease (IBD) that affects the large intestine (colon) and rectum which is characterized by inflammation and the formation of ulcers. It highlights companies such as AbbVie is developing Skyrizi; Janssen Pharmaceuticals, Tremfya; and Eli Lilly and Company, mirikizumab.

The article reports that the drug manufacturer GlaxoSmithKline announced that it had stopped enrollment in three phase clinical trials evaluating the company respiratory syncytial virus maternal vaccine candidate in pregnant women. Topics include considered that Syncytial is pronounced sin-SISH-uhl as the news comes after a February 18, 2022 pause in these trials following a recommendation from the independent data monitoring committee.

The article presents the discussion on experiencing or witnessing traumatic events such as military combat trauma, childhood trauma, and physical or sexual assault. Topics include nightmares, intrusive thoughts, ashbacks, hypervigilant behaviors, avoidance of traumatic reminders, and sleep disruptions; and promoting fear extinction learning and successfully establishing new safe associations with the original memory.

The article offers a review of the two drugs for the treatment of nonalcoholic steatohepatitis (NASH), a progressive form of nonalcoholic fatty liver disease (NAFLD), including the Ocaliva from Intercept Pharmaceuticals Inc. and the resmetirom from Madrigal Pharmaceuticals Inc.

The article informs that the U.S. Food & Drug Administration has approved mitapivat (Pyrukynd, Agios Pharmaceuticals) for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency, which is a lifelong and rare hemolytic anemia.

The article reports on the Fast-Track designation received by Bayer from the U.S. Food and Drug Administration (FDA) for its investigational anticoagulant asundexian (BAY243334). Topics discussed include information on asundexian, how to receive Fast Track designation, and clinical trials that are evaluating proper dosing and safety of asundexian.

The article presents the discussion on FDA approving baclofen oral suspension for the treatment of individuals with spasticity from multiple sclerosis (MS) or individuals with other spinal cord diseases or injuries. Topics include Fleqsuvy allowing for the lowest volume prescribed for patients showing the important consideration for suffering from dysphagi; and Fleqsuvy not indicating in the treatment of skeletal muscle spasm resulting from rheumatic disorders.

The article reports that Pfizer and BioNTech plans to extend their rolling submission to the U.S. Food and Drug Administration (FDA) seeking to amend the Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine to include children 6 months through 4 years of age. It mentions in light of the increase in reported COVID-19 cases and hospitalization in children younger during the surge of theomicron variant the FDA has requested for the same.

The article discusses approval of Quviviq tablets by Food & Drug Administration to treat adults with insomnia. Quviviq is a dual orexin receptor antagonist (DORA) that blocks neuropeptides orexin A and orexin B from binding to receptor sites. Insomnia is the most common sleep disorder in adults and approval of Quviviq is based on results of phase three trials.

The article reports that biologics target the inflammatory cytokines involved in the pathogenesis of asthma, a chronic respiratory disease that causes narrowing and inflammation of the airways that compromises breathing. Topics include corticosteroids can effectively treat asthma symptoms and exacerbations, their long-term use carries the risk of undesirable side effects, including osteoporosis and diabetes; and inhaled corticosteroids are not effective for those with noneosinophilic asthma.

The article discusses the late-stage trials of antibody-drug conjugate (ADC) oncology drugs that target cancer cells as of April 2023. Topics covered include the ADC components of a monoclonal antibody, a linker and a payload, and three additional ADCs comprised of HER3-DXd, Dato-DXd, and Teliso-V, aimed at fighting non-small cell lung cancer (NSCLC). Also noted are the expected final results dates of these trials.

The article focuses on San Francisco, California-based Gilead Sciences as the first line among the developers with magrolimab, which is a potential first-in class anti-CD47 antibody. Topics discussed include the test being made by Gilead on magrolimab in combination with Vidaza, a CD47 immune checkpoint inhibitor of Pfizer, and the effort by ALX Oncology to develop a CD47 immune checkpoint inhibitor.

The article discusses the growing treatment options for plaque psoriasis as of August 2022. Topics covered include the first approved nonsteroidal topical agent Vtama (tapinarof) cream 1%, the trials of the oral phosphodiesterase 4 (PDE4) Roflumilast cream, and the development of the first tyrosine kinase 2 (TYK2) inhibitor deucravacitinib oral treatment. Also noted are the promising results of the selective IL-17A and IL-17F inhibitor Bimzelx (bimekizumab).

The article discusses about the newer treatments under development, including chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies for multiple myeloma, a form of cancer. It mentions about the involvement of using the patient's own T cells to attack cancer cells in CAR-T therapy. It further reports on Pfizer's elranatamab as a B-cell maturation antigens (BCMAs) bispecific antibody under investigation for the potential treatment of multiple myeloma.